Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background. There are no approved drug treatments for liver fibrosis and nonalcoholic steatohepatitis (NASH), an advanced stage of fibrosis which has rapidly become a major cause of cirrhosis. Therefore, development of anti-inflammatory and antifibrotic therapies is desired. Mesenchymal stem cell- (MSC-) based therapy, which has been extensively investigated in regenerative medicine for various organs, can reportedly achieve therapeutic effect in NASH via paracrine action. Extracellular vesicles (EVs) encompass a variety of vesicles released by cells that fulfill functions similar to those of MSCs. We herein investigated the therapeutic effects of EVs from amnion-derived MSCs (AMSCs) in rats with NASH and liver fibrosis. Methods. NASH was induced by a 4-week high-fat diet (HFD), and liver fibrosis was induced by intraperitoneal injection of 2 mL/kg 50% carbon tetrachloride (CCl 4) twice a week for six weeks. AMSC-EVs were intravenously injected at weeks 3 and 4 in rats with NASH (15 μ g/kg) and at week 3 in rats with liver fibrosis (20 μ g/kg). The extent of inflammation and fibrosis was evaluated with quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The effect of AMSC-EVs on inflammatory and fibrogenic response was investigated in vitro. Results. AMSC-EVs significantly decreased the number of Kupffer cells (KCs) in the liver of rats with NASH and the mRNA expression levels of inflammatory cytokines such as tumor necrosis factor- (Tnf-) α, interleukin- (Il-) 1β and Il-6, and transforming growth factor- (Tgf-) β. Furthermore, AMSC-EVs significantly decreased fiber accumulation, KC number, and hepatic stellate cell (HSC) activation in rats with liver fibrosis. In vitro, AMSC-EVs significantly inhibited KC and HSC activation and suppressed the lipopolysaccharide (LPS)/toll-like receptor 4 (TLR4) signaling pathway. Conclusions. AMSC-EVs ameliorated inflammation and fibrogenesis in a rat model of NASH and liver fibrosis, potentially by attenuating HSC and KC activation. AMSC-EV administration should be considered as a new therapeutic strategy for chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms
Rőszer, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/816460 · Cited by 1,762
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 1×
“In addition, we demonstrated that AMSC-EVs suppressed the number of KCs that contribute to HSC activation and liver fibrosis [47].”
BackgroundNegative regulation of Toll-like receptor-mediated immune responses
Liew, F. Y., Xu, D., Brint, E. K., & O'Neill, L. A. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1630 · Cited by 1,509 · cited 1×
“In the LPS/TLR4 pathway, myeloid differential protein (MyD) 88 is activated, leading to TRAF6 activation and phosphorylation of p65 and IκB-α, allowing NF-κB to translocate to the nucleus [45, 46].”
BackgroundParacrine Mechanisms of Mesenchymal Stem Cell-Based Therapy: Current Status and Perspectives
Liang, X., Ding, Y., Zhang, Y., Tse, H.-F., & Lian, Q. (2014) · Cell Transplantation · doi:10.3727/096368913x667709 · Cited by 909
Eggenhofer, E., Benseler, V., Kroemer, A., Popp, F. C., Geissler, E. K., Schlitt, H. J., Baan, C. C., Dahlke, M. H., & Hoogduijn, M. J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00297 · Cited by 804 · cited 1×
“However, most of the transplanted cells are estimated not to actually reach target tissue, with most of the cells trapped in the lung, liver, and spleen [17].”
BackgroundMacrophage Phenotype as a Determinant of Biologic Scaffold Remodeling
Badylak, S. F., Valentin, J. E., Ravindra, A. K., McCabe, G. P., & Stewart-Akers, A. M. (2008) · Tissue Engineering Part A · doi:10.1089/ten.tea.2007.0264 · Cited by 729
Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T., & Nagy, L. E. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120026 · Cited by 628
Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S.-K., & Ho, H. K. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt465 · Cited by 548
Nooshabadi, V. T., Mardpour, S., Yousefi‐Ahmadipour, A., Allahverdi, A., Izadpanah, M., Daneshimehr, F., Ai, J., Banafshe, H. R., & Ebrahimi‐Barough, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26726 · Cited by 133
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Duarte, N., Coelho, I. C., Patarrão, R. S., Almeida, J. I., Penha-Gonçalves, C., & Macedo, M. P. (2015) · BioMed Research International · doi:10.1155/2015/984578 · Cited by 120 · cited 1×
“In the early stages of the disease, KCs expand rapidly and secrete cytokines and chemokines such as IL-1, TNF-α, MCP-1, and C-C motif chemokine ligand (CCL)5 [37], reflecting their involvement in the control of inflammatory responses in NASH and their major role in the recruitment of inflammatory cells in the liver [3…”
Background
Cited by
Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8121605 · Cited by 795
“MSC-EVs attenuated chronic liver inflammation by suppressing production of inflammatory cytokines (TNF-α, IL-1β and IL-6) and pro-fibrotic TGF-β1in liver macrophages (Kupffer cells), while HSCs were the main cellular targets in MSC-EVs-based alleviation of liver fibrosis [46].”
BackgroundKou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Psaraki, A., Ntari, L., Karakostas, C., Korrou‐Karava, D., & Roubelakis, M. G. (2022) · Hepatology · doi:10.1002/hep.32129 · Cited by 145
Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment
Yang, X., Li, Q., Liu, W., Zong, C., Wei, L., Shi, Y., & Han, Z. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00983-5 · Cited by 120
Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential
Liu, P., Mao, Y., Xie, Y., Wei, J., & Yao, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03041-5 · Cited by 82
Metadata
- Authors
- Ohara, M., Ohnishi, S., Hosono, H., Yamamoto, K., Yuyama, K., Nakamura, H., Fu, Q., Maehara, O., Suda, G., & Sakamoto, N.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2018-12-24
- Volume
- 2018
- Pages
- 1-15
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W2906567884
- Cited by
- 145
- References
- 12
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.